SCYX stock has shown mixed performance recently. The Q1 2024 earnings beat EPS expectations at $0.01 but missed revenue estimates significantly, which could limit bullish sentiment. However, the $10 million milestone payment expected from GSK in Q3 2024 and potential future payments under their agreement provide a positive long-term outlook. Current price levels may reflect cautious optimism.